| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 28 | 2022 | 5075 | 2.670 |
Why?
|
| Biometry | 18 | 2019 | 559 | 2.640 |
Why?
|
| Survival Analysis | 27 | 2022 | 10182 | 2.020 |
Why?
|
| Alzheimer Disease | 44 | 2024 | 8547 | 1.740 |
Why?
|
| Likelihood Functions | 16 | 2019 | 987 | 1.700 |
Why?
|
| Research Design | 13 | 2019 | 6180 | 1.340 |
Why?
|
| Proportional Hazards Models | 25 | 2024 | 12531 | 1.290 |
Why?
|
| Computer Simulation | 25 | 2023 | 6218 | 1.170 |
Why?
|
| Data Interpretation, Statistical | 15 | 2019 | 2696 | 1.160 |
Why?
|
| Clinical Trials as Topic | 15 | 2024 | 8056 | 1.070 |
Why?
|
| Statistics, Nonparametric | 6 | 2016 | 2852 | 0.970 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2016 | 473 | 0.910 |
Why?
|
| Biostatistics | 2 | 2015 | 164 | 0.890 |
Why?
|
| Neurofibrillary Tangles | 6 | 2022 | 457 | 0.830 |
Why?
|
| Amyloid beta-Peptides | 23 | 2023 | 3832 | 0.770 |
Why?
|
| Plaque, Amyloid | 11 | 2020 | 758 | 0.760 |
Why?
|
| Oligodendroglioma | 13 | 2010 | 279 | 0.710 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2020 | 10344 | 0.690 |
Why?
|
| Disease Progression | 25 | 2024 | 13502 | 0.670 |
Why?
|
| Bayes Theorem | 3 | 2017 | 2326 | 0.590 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2013 | 861 | 0.570 |
Why?
|
| Parkinson Disease | 8 | 2024 | 2859 | 0.570 |
Why?
|
| Accidents, Traffic | 2 | 2013 | 814 | 0.570 |
Why?
|
| Facial Paralysis | 1 | 2021 | 345 | 0.570 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2013 | 556 | 0.550 |
Why?
|
| DNA Copy Number Variations | 4 | 2016 | 2013 | 0.550 |
Why?
|
| tau Proteins | 9 | 2022 | 2085 | 0.530 |
Why?
|
| Wounds and Injuries | 3 | 2013 | 2477 | 0.520 |
Why?
|
| Apolipoprotein E4 | 6 | 2022 | 707 | 0.520 |
Why?
|
| Brain Neoplasms | 26 | 2018 | 8986 | 0.520 |
Why?
|
| Humans | 240 | 2024 | 760621 | 0.520 |
Why?
|
| Statistics as Topic | 3 | 2017 | 2362 | 0.500 |
Why?
|
| Epidemics | 1 | 2020 | 510 | 0.480 |
Why?
|
| Regression Analysis | 9 | 2019 | 6360 | 0.470 |
Why?
|
| Cerebral Amyloid Angiopathy | 10 | 2015 | 892 | 0.470 |
Why?
|
| Mortality | 2 | 2016 | 2916 | 0.470 |
Why?
|
| Apolipoproteins E | 9 | 2022 | 1436 | 0.460 |
Why?
|
| Case-Control Studies | 12 | 2019 | 22053 | 0.440 |
Why?
|
| Specimen Handling | 4 | 2012 | 707 | 0.440 |
Why?
|
| Research Subjects | 1 | 2015 | 249 | 0.440 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 258 | 0.430 |
Why?
|
| Sample Size | 6 | 2014 | 840 | 0.430 |
Why?
|
| Probability | 6 | 2022 | 2475 | 0.420 |
Why?
|
| Propylene Glycols | 1 | 2013 | 90 | 0.420 |
Why?
|
| Brain | 28 | 2022 | 26951 | 0.410 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 1997 | 186 | 0.410 |
Why?
|
| Acute Kidney Injury | 9 | 2017 | 1941 | 0.400 |
Why?
|
| Glioma | 9 | 2012 | 3420 | 0.400 |
Why?
|
| Rural Health | 1 | 2013 | 296 | 0.390 |
Why?
|
| Glioblastoma | 13 | 2018 | 3484 | 0.390 |
Why?
|
| Longitudinal Studies | 14 | 2024 | 14495 | 0.380 |
Why?
|
| Markov Chains | 4 | 2012 | 968 | 0.380 |
Why?
|
| Lectins | 3 | 2012 | 484 | 0.380 |
Why?
|
| Algorithms | 13 | 2018 | 13981 | 0.380 |
Why?
|
| Logistic Models | 10 | 2019 | 13314 | 0.370 |
Why?
|
| Genome, Human | 3 | 2016 | 4417 | 0.370 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 786 | 0.370 |
Why?
|
| Neurosciences | 1 | 2015 | 353 | 0.370 |
Why?
|
| Adipokines | 3 | 2012 | 311 | 0.370 |
Why?
|
| Aged | 99 | 2024 | 169152 | 0.370 |
Why?
|
| Sphingosine | 1 | 2013 | 308 | 0.360 |
Why?
|
| Models, Genetic | 5 | 2006 | 3442 | 0.360 |
Why?
|
| Cluster Analysis | 3 | 2009 | 2698 | 0.350 |
Why?
|
| Age of Onset | 8 | 2018 | 3301 | 0.350 |
Why?
|
| Linear Models | 3 | 2018 | 5877 | 0.350 |
Why?
|
| Dementia | 6 | 2024 | 2649 | 0.350 |
Why?
|
| Aged, 80 and over | 59 | 2024 | 58995 | 0.340 |
Why?
|
| Rural Health Services | 1 | 2013 | 381 | 0.340 |
Why?
|
| Homicide | 1 | 2012 | 295 | 0.330 |
Why?
|
| Amyloid | 5 | 2016 | 842 | 0.330 |
Why?
|
| Diagnostic Errors | 4 | 2013 | 1266 | 0.330 |
Why?
|
| Vaccination | 1 | 2021 | 3361 | 0.320 |
Why?
|
| Amyloidosis | 5 | 2019 | 817 | 0.310 |
Why?
|
| Genomics | 4 | 2022 | 5794 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 1 | 9 | 2012 | 635 | 0.310 |
Why?
|
| Placebos | 1 | 2013 | 1668 | 0.310 |
Why?
|
| Histology | 1 | 2007 | 16 | 0.310 |
Why?
|
| Apolipoprotein E2 | 2 | 2021 | 135 | 0.300 |
Why?
|
| Neurology | 1 | 2015 | 779 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2018 | 17790 | 0.280 |
Why?
|
| Male | 120 | 2024 | 359744 | 0.280 |
Why?
|
| Trauma Centers | 1 | 2012 | 933 | 0.280 |
Why?
|
| Monte Carlo Method | 6 | 2014 | 1257 | 0.270 |
Why?
|
| Female | 124 | 2024 | 391270 | 0.270 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 104 | 0.260 |
Why?
|
| Stroke | 8 | 2018 | 9962 | 0.260 |
Why?
|
| Neurilemmoma | 2 | 2008 | 523 | 0.250 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2007 | 220 | 0.250 |
Why?
|
| Numerical Analysis, Computer-Assisted | 2 | 2002 | 119 | 0.250 |
Why?
|
| Positron-Emission Tomography | 11 | 2023 | 6465 | 0.250 |
Why?
|
| Pneumonia | 2 | 2013 | 2131 | 0.250 |
Why?
|
| Calcineurin | 2 | 2018 | 229 | 0.240 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 1925 | 0.240 |
Why?
|
| Pure Autonomic Failure | 1 | 2024 | 16 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2005 | 662 | 0.240 |
Why?
|
| Mucolipidoses | 2 | 2015 | 82 | 0.240 |
Why?
|
| Cross Infection | 1 | 2013 | 1434 | 0.240 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 1304 | 0.230 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39261 | 0.230 |
Why?
|
| Middle Aged | 80 | 2024 | 220352 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2013 | 4166 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.220 |
Why?
|
| Multiple System Atrophy | 2 | 2024 | 129 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2013 | 916 | 0.220 |
Why?
|
| Immunohistochemistry | 16 | 2018 | 11071 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2013 | 2197 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 19 | 6 | 2009 | 347 | 0.210 |
Why?
|
| Genotype | 9 | 2021 | 12960 | 0.210 |
Why?
|
| Cognition | 7 | 2024 | 6957 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2024 | 168 | 0.210 |
Why?
|
| Lymphoma | 5 | 2013 | 1898 | 0.200 |
Why?
|
| Family Health | 1 | 2007 | 1257 | 0.200 |
Why?
|
| Siblings | 1 | 2006 | 824 | 0.200 |
Why?
|
| Dermatology | 2 | 2023 | 914 | 0.200 |
Why?
|
| Meningeal Neoplasms | 4 | 2013 | 1249 | 0.200 |
Why?
|
| Learning Curve | 1 | 2023 | 231 | 0.200 |
Why?
|
| Physical Fitness | 1 | 2006 | 732 | 0.200 |
Why?
|
| Creatinine | 3 | 2013 | 1903 | 0.190 |
Why?
|
| Neuropsychological Tests | 9 | 2022 | 7021 | 0.190 |
Why?
|
| Genetic Markers | 5 | 2008 | 2608 | 0.190 |
Why?
|
| Fallopian Tubes | 2 | 2012 | 178 | 0.190 |
Why?
|
| Aniline Compounds | 6 | 2017 | 1069 | 0.190 |
Why?
|
| Hemophilia A | 5 | 2003 | 359 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 4713 | 0.190 |
Why?
|
| Meningioma | 4 | 2012 | 1221 | 0.190 |
Why?
|
| Suicide | 1 | 2012 | 1599 | 0.190 |
Why?
|
| Cognition Disorders | 4 | 2016 | 3976 | 0.180 |
Why?
|
| Mice, Transgenic | 17 | 2019 | 9530 | 0.180 |
Why?
|
| Optic Nerve | 2 | 2015 | 567 | 0.180 |
Why?
|
| Genetic Linkage | 1 | 2006 | 2381 | 0.180 |
Why?
|
| Virus Latency | 2 | 2019 | 362 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2024 | 173 | 0.180 |
Why?
|
| Adult | 60 | 2024 | 219994 | 0.180 |
Why?
|
| DNA, Neoplasm | 5 | 2009 | 1745 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2018 | 9716 | 0.180 |
Why?
|
| Tauopathies | 2 | 2014 | 317 | 0.180 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 303 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2012 | 611 | 0.170 |
Why?
|
| Gene Expression Profiling | 8 | 2022 | 9411 | 0.170 |
Why?
|
| Time Factors | 16 | 2019 | 40165 | 0.170 |
Why?
|
| Neurons | 9 | 2019 | 9426 | 0.170 |
Why?
|
| Prognosis | 26 | 2024 | 29658 | 0.170 |
Why?
|
| Confidence Intervals | 6 | 2018 | 2932 | 0.170 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2023 | 423 | 0.170 |
Why?
|
| Synapses | 4 | 2019 | 1757 | 0.170 |
Why?
|
| Paraffin Embedding | 3 | 2012 | 302 | 0.170 |
Why?
|
| Neoplasms | 6 | 2019 | 22072 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 2660 | 0.170 |
Why?
|
| Twins | 1 | 2001 | 339 | 0.170 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 1648 | 0.160 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 632 | 0.160 |
Why?
|
| Family | 4 | 2014 | 3189 | 0.160 |
Why?
|
| Software | 5 | 2018 | 4419 | 0.160 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2010 | 122 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 280 | 0.160 |
Why?
|
| Cellulitis | 1 | 2020 | 207 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2018 | 1190 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2015 | 6544 | 0.160 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 42 | 0.150 |
Why?
|
| Visual Cortex | 2 | 2019 | 1089 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 844 | 0.150 |
Why?
|
| Autopsy | 3 | 2017 | 1007 | 0.150 |
Why?
|
| Retrospective Studies | 29 | 2024 | 80372 | 0.150 |
Why?
|
| Astrocytes | 5 | 2015 | 1338 | 0.150 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2018 | 69 | 0.150 |
Why?
|
| Weights and Measures | 2 | 2008 | 41 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 442 | 0.150 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 256 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2012 | 1764 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2014 | 9276 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2011 | 1218 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 3388 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2012 | 479 | 0.150 |
Why?
|
| Rheumatology | 1 | 2023 | 611 | 0.150 |
Why?
|
| Brain Ischemia | 3 | 2018 | 3127 | 0.140 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 448 | 0.140 |
Why?
|
| Microglia | 4 | 2015 | 1351 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 427 | 0.140 |
Why?
|
| Veterans | 2 | 2024 | 2642 | 0.140 |
Why?
|
| Propensity Score | 2 | 2021 | 1928 | 0.140 |
Why?
|
| Piperidines | 2 | 2023 | 1650 | 0.140 |
Why?
|
| Aging | 6 | 2019 | 8651 | 0.140 |
Why?
|
| Alopecia | 1 | 2021 | 414 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 214 | 0.140 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 5799 | 0.140 |
Why?
|
| Methylphenidate | 1 | 2020 | 488 | 0.140 |
Why?
|
| Cohort Studies | 19 | 2024 | 41335 | 0.130 |
Why?
|
| Amyloidogenic Proteins | 1 | 2017 | 151 | 0.130 |
Why?
|
| Olfactory Perception | 1 | 2016 | 65 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2016 | 3775 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 600 | 0.130 |
Why?
|
| Lewy Body Disease | 2 | 2024 | 252 | 0.130 |
Why?
|
| Calibration | 1 | 2018 | 816 | 0.130 |
Why?
|
| Bioethics | 1 | 1997 | 117 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 278 | 0.130 |
Why?
|
| Antigens, CD19 | 1 | 1999 | 424 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4291 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2007 | 2313 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5397 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2002 | 2648 | 0.130 |
Why?
|
| Memory | 2 | 2023 | 2179 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2000 | 1343 | 0.130 |
Why?
|
| Linkage Disequilibrium | 1 | 2000 | 1996 | 0.130 |
Why?
|
| Vitamin D | 2 | 2019 | 3291 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.130 |
Why?
|
| Cicatrix | 1 | 2021 | 782 | 0.130 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2014 | 13 | 0.130 |
Why?
|
| Prospective Studies | 18 | 2024 | 54303 | 0.130 |
Why?
|
| Health | 1 | 2018 | 396 | 0.120 |
Why?
|
| Retinal Dystrophies | 1 | 2015 | 64 | 0.120 |
Why?
|
| Nerve Degeneration | 2 | 2012 | 748 | 0.120 |
Why?
|
| Alleles | 5 | 2015 | 6898 | 0.120 |
Why?
|
| PAX2 Transcription Factor | 2 | 2012 | 86 | 0.120 |
Why?
|
| Chest Pain | 1 | 2022 | 1106 | 0.120 |
Why?
|
| Malpractice | 1 | 2020 | 556 | 0.120 |
Why?
|
| Metformin | 1 | 2022 | 912 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12159 | 0.120 |
Why?
|
| Hospitals | 2 | 2020 | 3928 | 0.120 |
Why?
|
| Hospital Mortality | 4 | 2022 | 5425 | 0.120 |
Why?
|
| HIV Infections | 11 | 2019 | 17165 | 0.120 |
Why?
|
| Knee Joint | 1 | 2023 | 1663 | 0.120 |
Why?
|
| Renal Replacement Therapy | 2 | 2014 | 281 | 0.120 |
Why?
|
| NFATC Transcription Factors | 2 | 2018 | 381 | 0.120 |
Why?
|
| Memory Disorders | 2 | 2023 | 1197 | 0.120 |
Why?
|
| AIDS-Related Complex | 1 | 2014 | 107 | 0.120 |
Why?
|
| Dental Impression Materials | 1 | 2014 | 37 | 0.120 |
Why?
|
| Gliosis | 2 | 2014 | 244 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 15789 | 0.120 |
Why?
|
| Mosaicism | 3 | 2012 | 466 | 0.120 |
Why?
|
| Microvessels | 1 | 2018 | 572 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 1375 | 0.120 |
Why?
|
| Risk | 5 | 2023 | 9631 | 0.110 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 93 | 0.110 |
Why?
|
| Renal Dialysis | 4 | 2016 | 1801 | 0.110 |
Why?
|
| Twins, Monozygotic | 2 | 2009 | 469 | 0.110 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2015 | 266 | 0.110 |
Why?
|
| Carbolines | 1 | 2015 | 288 | 0.110 |
Why?
|
| Treatment Outcome | 19 | 2024 | 65017 | 0.110 |
Why?
|
| Dental Impression Technique | 1 | 2014 | 59 | 0.110 |
Why?
|
| Home Care Services | 1 | 2020 | 654 | 0.110 |
Why?
|
| Adolescent | 25 | 2024 | 87810 | 0.110 |
Why?
|
| DNA, Mitochondrial | 2 | 2012 | 858 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2012 | 2506 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15757 | 0.110 |
Why?
|
| Prevalence | 5 | 2024 | 15687 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 404 | 0.110 |
Why?
|
| Chromosome Deletion | 3 | 2009 | 1387 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2717 | 0.110 |
Why?
|
| United States | 12 | 2024 | 72461 | 0.110 |
Why?
|
| Caffeine | 1 | 2018 | 702 | 0.110 |
Why?
|
| Nervous System Diseases | 2 | 2014 | 1647 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2019 | 1110 | 0.110 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 18137 | 0.110 |
Why?
|
| Dendrites | 2 | 2012 | 475 | 0.110 |
Why?
|
| Models, Biological | 5 | 2020 | 9467 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2006 | 649 | 0.110 |
Why?
|
| Receptors, Virus | 2 | 2014 | 639 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2017 | 8950 | 0.100 |
Why?
|
| Antibodies | 2 | 2014 | 2421 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 640 | 0.100 |
Why?
|
| Dendritic Spines | 2 | 2013 | 243 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3465 | 0.100 |
Why?
|
| Young Adult | 16 | 2024 | 58741 | 0.100 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 14660 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 893 | 0.100 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2013 | 146 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2000 | 2611 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2017 | 732 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 2061 | 0.100 |
Why?
|
| Adenovirus Infections, Human | 1 | 2013 | 73 | 0.100 |
Why?
|
| HIV | 1 | 2019 | 1579 | 0.100 |
Why?
|
| Dental Prosthesis Design | 1 | 2014 | 264 | 0.100 |
Why?
|
| Agglutinins | 2 | 2002 | 28 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2021 | 1089 | 0.100 |
Why?
|
| Computer-Aided Design | 1 | 2014 | 302 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 535 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 6315 | 0.100 |
Why?
|
| Extracellular Fluid | 1 | 2013 | 165 | 0.100 |
Why?
|
| Risk Factors | 19 | 2024 | 74359 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 367 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2024 | 2890 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2018 | 1233 | 0.100 |
Why?
|
| Cytomegalovirus | 3 | 2002 | 755 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2180 | 0.100 |
Why?
|
| Boston | 4 | 2023 | 9280 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2250 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2002 | 2688 | 0.100 |
Why?
|
| Formaldehyde | 2 | 2010 | 358 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 2007 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2023 | 3016 | 0.100 |
Why?
|
| Membrane Glycoproteins | 3 | 2014 | 3707 | 0.090 |
Why?
|
| Loss of Heterozygosity | 4 | 2006 | 659 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2002 | 2569 | 0.090 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 1469 | 0.090 |
Why?
|
| Pathology, Surgical | 1 | 2012 | 151 | 0.090 |
Why?
|
| Methotrexate | 3 | 2008 | 1719 | 0.090 |
Why?
|
| Thiazoles | 5 | 2017 | 1511 | 0.090 |
Why?
|
| Adenoviruses, Human | 1 | 2013 | 255 | 0.090 |
Why?
|
| Neuroglia | 4 | 2019 | 944 | 0.090 |
Why?
|
| Fixatives | 1 | 2010 | 91 | 0.090 |
Why?
|
| Mutation | 12 | 2022 | 29932 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2016 | 1489 | 0.090 |
Why?
|
| Mice | 23 | 2019 | 81208 | 0.090 |
Why?
|
| Vitamins | 1 | 2019 | 1634 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 20080 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 1999 | 1403 | 0.090 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2005 | 245 | 0.090 |
Why?
|
| Predictive Value of Tests | 12 | 2012 | 15289 | 0.090 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1826 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 11152 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 350 | 0.090 |
Why?
|
| Animals | 27 | 2019 | 167963 | 0.090 |
Why?
|
| Cerebral Cortex | 2 | 2017 | 5761 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 2 | 1999 | 59 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2021 | 1528 | 0.090 |
Why?
|
| Regeneration | 1 | 2019 | 1506 | 0.090 |
Why?
|
| Hippocampus | 3 | 2018 | 3738 | 0.090 |
Why?
|
| Survival Rate | 10 | 2020 | 12808 | 0.090 |
Why?
|
| New York City | 2 | 2023 | 724 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 4 | 2005 | 276 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 3 | 2002 | 831 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 1999 | 76 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 248 | 0.080 |
Why?
|
| Nitriles | 1 | 2014 | 956 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 618 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2012 | 328 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2007 | 1268 | 0.080 |
Why?
|
| Myasthenia Gravis | 1 | 2012 | 213 | 0.080 |
Why?
|
| Quinolines | 1 | 2014 | 759 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2012 | 1343 | 0.080 |
Why?
|
| Comorbidity | 1 | 2024 | 10551 | 0.080 |
Why?
|
| Hematoma | 1 | 2014 | 769 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2013 | 658 | 0.080 |
Why?
|
| Injury Severity Score | 1 | 2012 | 1033 | 0.080 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 254 | 0.080 |
Why?
|
| Ear, External | 1 | 2009 | 164 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2012 | 916 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2022 | 36290 | 0.080 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2008 | 60 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2007 | 2802 | 0.080 |
Why?
|
| Breast Neoplasms | 6 | 2007 | 21025 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1501 | 0.080 |
Why?
|
| Retinal Degeneration | 1 | 2012 | 412 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 982 | 0.080 |
Why?
|
| Seizures | 1 | 2021 | 2917 | 0.080 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1274 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 6828 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 820 | 0.080 |
Why?
|
| Apolipoprotein E3 | 2 | 2021 | 107 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 2167 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2363 | 0.080 |
Why?
|
| Acetylglucosaminidase | 1 | 2007 | 67 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 7 | 2007 | 6068 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 1526 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1602 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2006 | 2448 | 0.070 |
Why?
|
| Natural Language Processing | 1 | 2016 | 1135 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 567 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2004 | 1117 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 2733 | 0.070 |
Why?
|
| Mothers | 1 | 2018 | 2186 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 370 | 0.070 |
Why?
|
| Drainage | 1 | 2013 | 1161 | 0.070 |
Why?
|
| False Negative Reactions | 2 | 2013 | 573 | 0.070 |
Why?
|
| Topotecan | 1 | 2007 | 132 | 0.070 |
Why?
|
| Sputum | 2 | 1999 | 503 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2634 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 795 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 12293 | 0.070 |
Why?
|
| Life Tables | 1 | 2007 | 365 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2007 | 194 | 0.070 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 134 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2010 | 733 | 0.070 |
Why?
|
| Dipeptides | 1 | 2009 | 409 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2782 | 0.070 |
Why?
|
| Atrophy | 4 | 2016 | 1627 | 0.070 |
Why?
|
| Hospital Shared Services | 1 | 2006 | 16 | 0.070 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 806 | 0.070 |
Why?
|
| Presenilin-1 | 3 | 2019 | 660 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2018 | 3615 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 22023 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2024 | 4744 | 0.070 |
Why?
|
| Life Style | 1 | 2018 | 3896 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 461 | 0.070 |
Why?
|
| DNA-Binding Proteins | 5 | 2008 | 9585 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2004 | 698 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1132 | 0.070 |
Why?
|
| Telephone | 1 | 2009 | 624 | 0.070 |
Why?
|
| Gene Order | 1 | 2006 | 169 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2008 | 345 | 0.070 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2008 | 254 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2006 | 203 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2009 | 551 | 0.060 |
Why?
|
| Mood Disorders | 2 | 2004 | 1124 | 0.060 |
Why?
|
| Twins, Dizygotic | 2 | 2009 | 236 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15840 | 0.060 |
Why?
|
| Transfection | 1 | 2013 | 5781 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3844 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 8035 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 6015 | 0.060 |
Why?
|
| Neuroma, Acoustic | 1 | 2009 | 459 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2014 | 2415 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 977 | 0.060 |
Why?
|
| Ependymoma | 1 | 2008 | 320 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 755 | 0.060 |
Why?
|
| Astrocytoma | 2 | 2006 | 775 | 0.060 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13630 | 0.060 |
Why?
|
| Dopamine | 1 | 2012 | 1595 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 186 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4407 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 279 | 0.060 |
Why?
|
| Esophagectomy | 2 | 2006 | 466 | 0.060 |
Why?
|
| Transcription Factors | 4 | 2011 | 12103 | 0.060 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 244 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2659 | 0.060 |
Why?
|
| Celiac Disease | 1 | 2013 | 822 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 326 | 0.060 |
Why?
|
| Axons | 1 | 2012 | 1673 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2007 | 616 | 0.060 |
Why?
|
| Ischemia | 1 | 2013 | 1893 | 0.060 |
Why?
|
| Pneumocystis carinii | 1 | 2005 | 72 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 551 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2005 | 183 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2011 | 724 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 1885 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5201 | 0.060 |
Why?
|
| Transient Receptor Potential Channels | 2 | 2015 | 130 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2005 | 177 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 560 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2471 | 0.060 |
Why?
|
| Child | 11 | 2021 | 79806 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2290 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11712 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2000 | 955 | 0.060 |
Why?
|
| Artifacts | 1 | 2012 | 1898 | 0.060 |
Why?
|
| Gene Deletion | 4 | 2005 | 2668 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 442 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8624 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5697 | 0.060 |
Why?
|
| Perineum | 1 | 2005 | 208 | 0.060 |
Why?
|
| Anxiety | 1 | 2018 | 4538 | 0.050 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 25942 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1871 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 3531 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2020 | 12914 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 306 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2018 | 24123 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11891 | 0.050 |
Why?
|
| Keratosis, Seborrheic | 1 | 2003 | 27 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2005 | 399 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 725 | 0.050 |
Why?
|
| Feces | 2 | 1999 | 1455 | 0.050 |
Why?
|
| Anti-HIV Agents | 5 | 2000 | 4491 | 0.050 |
Why?
|
| Nuclear Family | 1 | 2004 | 313 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 329 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 3193 | 0.050 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2002 | 10 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2006 | 859 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1913 | 0.050 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 62 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 727 | 0.050 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2024 | 84 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2006 | 536 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2005 | 1085 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2009 | 779 | 0.050 |
Why?
|
| Homeostasis | 1 | 2013 | 3306 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Quality of Life | 1 | 2024 | 13308 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 533 | 0.050 |
Why?
|
| Maternal Age | 1 | 2005 | 807 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 877 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 1055 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2012 | 3602 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20509 | 0.050 |
Why?
|
| Philosophy | 1 | 2002 | 68 | 0.050 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2003 | 133 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1439 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2003 | 167 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2009 | 780 | 0.050 |
Why?
|
| Papillomavirus Infections | 2 | 2004 | 1607 | 0.050 |
Why?
|
| Live Birth | 1 | 2005 | 512 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1246 | 0.050 |
Why?
|
| Factor VII | 1 | 2002 | 139 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 568 | 0.050 |
Why?
|
| Retina | 1 | 2012 | 2635 | 0.050 |
Why?
|
| Cause of Death | 1 | 2012 | 3725 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2006 | 1631 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4878 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 287 | 0.050 |
Why?
|
| Selection Bias | 1 | 2003 | 358 | 0.050 |
Why?
|
| Ferritins | 1 | 2024 | 597 | 0.050 |
Why?
|
| Integrins | 1 | 2005 | 839 | 0.050 |
Why?
|
| Pokeweed Mitogens | 1 | 2000 | 38 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 429 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2022 | 221 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2022 | 190 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2005 | 329 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3696 | 0.050 |
Why?
|
| DNA Probes | 2 | 2012 | 551 | 0.050 |
Why?
|
| Glycoproteins | 2 | 2006 | 2208 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 248 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2021 | 3061 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2024 | 886 | 0.050 |
Why?
|
| Diagnosis, Differential | 7 | 2013 | 12965 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 232 | 0.040 |
Why?
|
| Streptokinase | 1 | 2000 | 187 | 0.040 |
Why?
|
| Calcium | 1 | 2013 | 5725 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 438 | 0.040 |
Why?
|
| Age Factors | 6 | 2018 | 18416 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 1122 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 193 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 1056 | 0.040 |
Why?
|
| Diet | 1 | 2018 | 8010 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2012 | 23376 | 0.040 |
Why?
|
| Compensation and Redress | 1 | 2020 | 66 | 0.040 |
Why?
|
| ROC Curve | 3 | 2013 | 3568 | 0.040 |
Why?
|
| Candida | 1 | 2000 | 173 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3426 | 0.040 |
Why?
|
| Zidovudine | 2 | 2000 | 624 | 0.040 |
Why?
|
| Point Mutation | 1 | 2004 | 1594 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 618 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 4573 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 412 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4775 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 1975 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 42063 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2000 | 268 | 0.040 |
Why?
|
| DNA Mutational Analysis | 4 | 2012 | 4107 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 961 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2004 | 587 | 0.040 |
Why?
|
| Body Temperature | 1 | 2022 | 777 | 0.040 |
Why?
|
| Transportation | 1 | 2000 | 214 | 0.040 |
Why?
|
| Cell Division | 3 | 2001 | 4463 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2009 | 2560 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2014 | 3600 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2006 | 550 | 0.040 |
Why?
|
| Abdomen | 1 | 2005 | 1130 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2022 | 805 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2004 | 679 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2000 | 415 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2005 | 1334 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 877 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2002 | 580 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2020 | 210 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 1613 | 0.040 |
Why?
|
| Estradiol | 1 | 2005 | 1932 | 0.040 |
Why?
|
| Esthetics | 1 | 2000 | 326 | 0.040 |
Why?
|
| Neopterin | 1 | 1997 | 56 | 0.040 |
Why?
|
| Didanosine | 1 | 1998 | 151 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2001 | 336 | 0.040 |
Why?
|
| Proteinuria | 1 | 2001 | 594 | 0.040 |
Why?
|
| Genome | 1 | 2006 | 1739 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 3 | 2013 | 1067 | 0.040 |
Why?
|
| Benzene Derivatives | 2 | 2009 | 53 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 1997 | 33 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3106 | 0.040 |
Why?
|
| Ultrafiltration | 1 | 1997 | 49 | 0.040 |
Why?
|
| Alkenes | 2 | 2009 | 54 | 0.040 |
Why?
|
| Population Growth | 1 | 1997 | 50 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2003 | 2608 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2005 | 12427 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2006 | 2533 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 1755 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3790 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 657 | 0.040 |
Why?
|
| Thiones | 1 | 2017 | 46 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 1999 | 220 | 0.040 |
Why?
|
| Fertilization in Vitro | 1 | 2005 | 1292 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 372 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 536 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 1137 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 1998 | 238 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7850 | 0.040 |
Why?
|
| Medical Records | 1 | 2022 | 1407 | 0.040 |
Why?
|
| Palmitates | 1 | 2017 | 70 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2005 | 1824 | 0.040 |
Why?
|
| Photic Stimulation | 2 | 2014 | 1967 | 0.030 |
Why?
|
| Propranolol | 1 | 1998 | 489 | 0.030 |
Why?
|
| Hemodiafiltration | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1999 | 780 | 0.030 |
Why?
|
| Stilbenes | 2 | 2009 | 155 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2012 | 1636 | 0.030 |
Why?
|
| Evoked Potentials, Visual | 1 | 2019 | 415 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2004 | 2919 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2018 | 3380 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 1997 | 354 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2005 | 3682 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2002 | 1617 | 0.030 |
Why?
|
| Hospitalization | 2 | 2013 | 10790 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8482 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 2825 | 0.030 |
Why?
|
| Disease | 1 | 2001 | 671 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 979 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2009 | 4490 | 0.030 |
Why?
|
| Sarcoma | 1 | 2006 | 1786 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 416 | 0.030 |
Why?
|
| Microdissection | 2 | 2005 | 151 | 0.030 |
Why?
|
| Triage | 1 | 2022 | 987 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2018 | 12766 | 0.030 |
Why?
|
| Entorhinal Cortex | 1 | 2016 | 286 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2014 | 245 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 363 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2005 | 1463 | 0.030 |
Why?
|
| Lameness, Animal | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1999 | 1247 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1628 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 613 | 0.030 |
Why?
|
| Infant | 4 | 2021 | 36060 | 0.030 |
Why?
|
| Calcium Sulfate | 1 | 2014 | 24 | 0.030 |
Why?
|
| Spirometry | 1 | 1997 | 924 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 389 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 2272 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 4433 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 10827 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11345 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2014 | 212 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 517 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 587 | 0.030 |
Why?
|
| Neurites | 1 | 2015 | 390 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2013 | 225 | 0.030 |
Why?
|
| Dental Materials | 1 | 2014 | 113 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 314 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 173 | 0.030 |
Why?
|
| Massachusetts | 2 | 2019 | 8803 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 3610 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 8515 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 273 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2006 | 3598 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 1189 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1630 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 759 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2012 | 43 | 0.030 |
Why?
|
| Patient Preference | 1 | 2020 | 922 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 1999 | 1468 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 263 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 1902 | 0.030 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2015 | 5039 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 1928 | 0.030 |
Why?
|
| DNA Repair Enzymes | 2 | 2007 | 345 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 1259 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2012 | 317 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 982 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 477 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 86 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2013 | 2194 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 2213 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 2018 | 1036 | 0.030 |
Why?
|
| Telemedicine | 1 | 2009 | 3018 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2007 | 3204 | 0.030 |
Why?
|
| Parents | 1 | 2006 | 3549 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10547 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2012 | 162 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1999 | 1810 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2932 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 835 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2012 | 370 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 2471 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12626 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 1705 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 956 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 1972 | 0.020 |
Why?
|
| Intravitreal Injections | 1 | 2012 | 384 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 468 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 697 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 321 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1999 | 2838 | 0.020 |
Why?
|
| Educational Status | 1 | 2018 | 2515 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 2014 | 652 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 786 | 0.020 |
Why?
|
| Capillaries | 1 | 2013 | 744 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3529 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2012 | 932 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 153 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2005 | 2421 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2502 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 1365 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 3150 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 897 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2015 | 14372 | 0.020 |
Why?
|
| Registries | 1 | 2006 | 8469 | 0.020 |
Why?
|
| Fluorescent Dyes | 2 | 2009 | 1913 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 865 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 73 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2006 | 5870 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1407 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2012 | 1095 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 1006 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 454 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2108 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4048 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2421 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 161 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2536 | 0.020 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 542 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 315 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3562 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 11903 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 250 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 250 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2012 | 708 | 0.020 |
Why?
|
| Quinazolines | 1 | 2014 | 1363 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 994 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2015 | 1688 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 4938 | 0.020 |
Why?
|
| Brain Stem | 1 | 2013 | 857 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2012 | 589 | 0.020 |
Why?
|
| Minocycline | 1 | 2009 | 168 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 1690 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 5496 | 0.020 |
Why?
|
| Dependovirus | 1 | 2012 | 709 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 601 | 0.020 |
Why?
|
| Neocortex | 1 | 2011 | 416 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 1547 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2913 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8555 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 1735 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 289 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 368 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2057 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2009 | 234 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 988 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3736 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4541 | 0.020 |
Why?
|
| Neurofibromin 2 | 1 | 2008 | 270 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1388 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2006 | 107 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2018 | 1394 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 493 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 818 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 6853 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 352 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 392 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 3865 | 0.020 |
Why?
|
| Skin Window Technique | 1 | 2006 | 22 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 1187 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3505 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 209 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1496 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5643 | 0.020 |
Why?
|
| Paxillin | 1 | 2005 | 86 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5125 | 0.020 |
Why?
|
| Incidence | 2 | 2016 | 21392 | 0.020 |
Why?
|
| Dental Implants | 1 | 2014 | 791 | 0.020 |
Why?
|
| Coenzymes | 1 | 2005 | 102 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 4742 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 384 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6538 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2005 | 115 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5305 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 516 | 0.020 |
Why?
|
| Hearing | 1 | 2009 | 501 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2775 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3340 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6216 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 160 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 2924 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2005 | 159 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 211 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2004 | 119 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 2234 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2005 | 428 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 285 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 704 | 0.010 |
Why?
|
| Motor Activity | 1 | 2014 | 2687 | 0.010 |
Why?
|
| Inflammation | 1 | 2024 | 10756 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 419 | 0.010 |
Why?
|
| Meninges | 1 | 2006 | 197 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 474 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 3075 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2005 | 369 | 0.010 |
Why?
|
| DNA | 2 | 2009 | 7233 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 330 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2803 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1050 | 0.010 |
Why?
|
| Syndecans | 1 | 2003 | 75 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2014 | 3040 | 0.010 |
Why?
|
| Oxygen | 1 | 2014 | 4193 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8158 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 616 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2005 | 713 | 0.010 |
Why?
|
| Cyclin E | 1 | 2003 | 155 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2007 | 1180 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4264 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2884 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 191 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2262 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 7818 | 0.010 |
Why?
|
| Vindesine | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2006 | 780 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2003 | 163 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 15697 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 763 | 0.010 |
Why?
|
| Vitrectomy | 1 | 2005 | 391 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4899 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 18957 | 0.010 |
Why?
|
| Vasodilation | 1 | 2006 | 962 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 13451 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7408 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 391 | 0.010 |
Why?
|
| Synucleins | 1 | 2001 | 107 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2828 | 0.010 |
Why?
|
| Colombia | 1 | 2002 | 276 | 0.010 |
Why?
|
| Interferon Regulatory Factors | 1 | 2003 | 260 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 495 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2002 | 777 | 0.010 |
Why?
|
| HIV-1 | 1 | 1999 | 6849 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2176 | 0.010 |
Why?
|
| Oleic Acid | 1 | 2001 | 92 | 0.010 |
Why?
|
| Craniotomy | 1 | 2006 | 741 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2138 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 631 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 17624 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3078 | 0.010 |
Why?
|
| Zalcitabine | 1 | 2000 | 43 | 0.010 |
Why?
|
| Autoantigens | 1 | 2005 | 877 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 1835 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 582 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1139 | 0.010 |
Why?
|
| Base Sequence | 1 | 2011 | 12446 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1006 | 0.010 |
Why?
|
| Neprilysin | 1 | 2003 | 472 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 801 | 0.010 |
Why?
|
| Xenobiotics | 1 | 1999 | 71 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 15620 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2020 | 5870 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 2897 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6479 | 0.010 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2001 | 296 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 3455 | 0.010 |
Why?
|
| RNA | 1 | 2009 | 2722 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 4169 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5961 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2014 | 6551 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 426 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 2186 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 2819 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3800 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 26181 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 2392 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 934 | 0.010 |
Why?
|
| Mitogens | 1 | 1998 | 230 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2013 | 6381 | 0.010 |
Why?
|
| Cytosol | 1 | 2001 | 887 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 2003 | 564 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6377 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2893 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1341 | 0.010 |
Why?
|
| Obesity | 1 | 2020 | 12922 | 0.010 |
Why?
|
| Cysteine | 1 | 2002 | 895 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1999 | 796 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 2414 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 3735 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2753 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2012 | 6568 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3726 | 0.010 |
Why?
|
| Body Weight | 1 | 1987 | 4611 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6238 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7588 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 4122 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16546 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1788 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2221 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1999 | 557 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2001 | 854 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 1644 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 2798 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2001 | 1115 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 4090 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2176 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2001 | 749 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 1475 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2005 | 2869 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8552 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16939 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11481 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3334 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2003 | 1223 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 2809 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1403 | 0.010 |
Why?
|
| Cell Separation | 1 | 1998 | 1720 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4625 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13262 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 3600 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 3959 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 2003 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5791 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 1827 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10446 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 9287 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3336 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 6498 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 23711 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29749 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 9335 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1987 | 197 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1998 | 4897 | 0.000 |
Why?
|
| Body Height | 1 | 1987 | 1570 | 0.000 |
Why?
|